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ABSTRACT: We analyzed the ligand binding specificity of the lymphocyte specific kinase (Lck) SH3 domain.
We identified artificial Lck SH3 ligands using phage display. In addition, we analyzed Lck SH3 binding
sites within known natural Lck SH3 binding proteins using an Lck specific binding assay on membrane-
immobilized synthetic peptides. On one hand, from the phage-selected peptides, representing mostly special
class I′ ligands, a well-defined consensus sequence was obtained. Interestingly, a histidine outside the
central polyproline motif contributes significantly to Lck SH3 binding affinity and specificity. On the
other hand, we confirmed previously mapped Lck SH3 binding sites in ADAM15, HS1, SLP76, and
NS5A, and identified putative Lck SH3 binding sites of Sam68, FasL, c-Cbl, and Cbl-b. Without exception,
the comparatively diverse Lck SH3 binding sites of all analyzed natural Lck SH3 binding proteins emerged
as class II proteins. Possible explanations for the observed variations between artificial and native ligandss
which are not due to significant KD value differences as shown by calculating Lck SH3 affinities of
artificial peptide PD1-Y(-3)R as well as for peptides comprising putative Lck SH3 binding sites of NS5A,
Sos, and Sam68sare discussed. Our data suggest that phage display, a popular tool for determining SH3
binding specificity, mustsat least in the case of Lcksnot irrevocably mirror physiologically relevant
protein-ligand interactions.
Protein tyrosine kinases (PTKs)1 are involved in signal
transduction pathways that regulate cell growth, differentia-
tion, activation, and transformation. Lck is a lymphoid
specific PTK, which is essential for T-cell development and
function (1-3). Lck resides predominantly in the cytosol
where it interacts with the inner side of the plasma membrane
via its hydrophobic myristoylated NH2 terminus (4). It is
constitutively associated with the cytoplasmic portions of cell
surface receptors CD4 and CD8 (5, 6) and plays a key role
in T-cell antigen receptor (TCR)-linked signal transduction
pathways (7). As a member of the Src family of kinases,
Lck shows their common architecture consisting of an
N-terminal unique domain, followed by the regulatory SH3
and SH2 domains and by the tyrosine kinase domain
containing the active site. The SH3 domain binds to
polyproline motifs and is required for association of the
kinase with many intracellular substrate or binding partners.
Various Lck SH3 domain interacting proteins have been
reported, e.g., c-Cbl (8, 9), CD28 (10), PI3K (11), HS1/
LckBP1 (12), SLP-76 (13), CD2 (14), Sos (15), ADAM15
(16), NS4A (17), MAP kinase (18), hDlg (19), and Sam-68
(20). So far, only for some of them have exact binding sites
for Lck SH3 been experimentally mapped. Therefore, no
prediction of a consensus sequence for Lck SH3 binding
ligands has been deduced up to now.
The Protein Data Bank (PDB) includes the structures of
almost 30 different SH3 domains, many of them determined
repeatedly from the same organism or from different organ-
isms. Additionally, the structures of more then 20 SH3
domains with physiologically relevant or engineered ligands
have been deposited. As known from these complex struc-
tures, binding of polyproline SH3 ligands occurs at a shallow
hydrophobic patch formed by residues of the SH3 RT loop,
the n-src loop, and the turn connecting strands â4 and â5
(21). SH3 ligands are pseudosymmetrical and may therefore
bind in one of two opposite orientations (22, 23). Ligands
that bind in one orientation or the other are divided into
different classes. Class I ligands conform to the consensus
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+p¾Pp¾P and class II ligands to ¾Pp¾Pp+, where the
uppercase positions represent conserved residues that contact
the SH3 domain and confer specificity and the lowercase
residues represent scaffolding residues that tend to be proline.
¾ and + represent sequence positions occupied by aliphatic
and basic residues, respectively. Particularly the position of
the basic residue, mostly an arginine, relative to the core
proline residues determines ligand orientation (24). More
recently, several exceptions have been described (25),
suggesting that the binding potential of SH3 domains might
be larger than anticipated so far.
Specificities of a great number of SH3 domains have been
determined by screening of a phage-displayed peptide library
or immobilized synthetic peptide arrays. Thus, ligand prefer-
ences of the SH3 domains of Src (25-29), Yes, Fyn, Lyn
(30, 31), PI3K (31), Grb2-N, Grb2-C, p53bp2, Cortactin, Crk,
Abl, PlCç (30), Itk (32), Cap (33), Eps8 (34), amphysin,
endophilin (35), and Abp1 (36), have been published.
Recently, several comprehensive surveys have covered the
functional and structural aspects of SH3-mediated interac-
tions (37-40), and extensive systematic approaches have
been undertaken to make the peptide recognition specificity
mediated by SH3 domains predictable (41, 42). The previ-
ously available data do not support the idea of a simple
recognition code (25). Nevertheless, some recognition rules
began to emerge, and SH3 domains from the entire yeast
repertoire could tentatively be assigned to eight different
specificity classes (25). Statistical methods based on position
specific profiles (42) or neural networks (41) still cannot
provide highly confident results due to the lack of “balanced”
input data.
In the case of Lck SH3, no screenings of phage-displayed
randomized peptide libraries or combinatorial synthetic
peptide arrays were reported so far. We therefore analyzed
the ligand binding specificity of the Lck SH3 domain by
searching for artificial peptide ligands screening a phage
display peptide library. Additionally, we analyzed a variety
of Lck SH3 binding sites in nearly every known and
sufficiently characterized cellular Lck SH3 binding partner
using membrane-immobilized synthetic peptides. A com-
parison of the two data sets should afford deeper insights
into Lck SH3 binding specificity, as possibly can be obtained
by the common phage display approach alone.
MATERIALS AND METHODS
Preparation of Glutathione S-Transferase (GST)-SH3
Fusion Proteins. The expression system for the GST-Lck
SH3 fusion protein was described previously (43, 44). DNA
constructs encoding GST fusions to the Fyn (aa 80-146),
Hck (aa 61-141), PI3K (aa 1-83), Src (aa 79-150), and
Abl (aa 59-126) SH3 domains were generated by PCR
cloning of the appropriate DNA fragments using IMAGE
cDNA clones IMAGp998C136535, IMAGp958H201705,
IMAGp998J21580, IMAGp998N195197, and DKFZp762G2-
44Q, respectively. PCR fragments were digested with BamHI
and XhoI and inserted into pGEX-6P-2 (Amersham Bio-
sciences, Freiburg, Germany). Integrities of the constructs
were confirmed by DNA sequencing. GST-SH3 fusions and
free SH3 domains were prepared essentially as described
previously for the GST-Lck SH3 fusion protein (43, 44).
Only thrombin cleavage was replaced by a PreScission
protease (Amersham Biosciences) cleavage. The identities
of the SH3 domains were confirmed by mass spectroscopy.
Purity of the proteins was checked by SDS-PAGE. Con-
centrations of all protein solutions were determined according
to their absorbance at 280 nm (45).
Biopanning. A commercially available peptide library kit
(PhD.-12 Peptide Library Kit, New England Biolabs, Inc.,
Beverly, MA) containing 2.7  109 independent clones was
used to perform the biopanning by following the manufac-
turer’s instructions (Instruction manual, version 2.7) with
minor modifications: the commonly used TBS buffer [50
mM Tris-HCl (pH 7.7) and 150 mM NaCl] and the 0.1 M
NaHCO3 solution for target immobilization were replaced
with a Tris-Bis buffer [20 mM Bis-Tris (pH 6.5), 150 mM
NaCl, and 1 mM BME]. Recombinant GST-Lck SH3 fusion
protein was used as bait. Progress of affinity selection was
tracked using the anti-phage ELISA detection system de-
scribed in detail below.
Determination of Lck SH3 Binding ActiVity of Enriched
Sublibraries or Single Affinity-Purified Phage Clones (anti-
phage ELISA). Proteins at a concentration of 10 íg/mL in
Tris-Bis were immobilized on microtiter plates overnight at
4 °C. Remaining binding sites were blocked with blocking
buffer (Bis-Tris supplemented with 10 mg/mL BSA) for 2
h. Here, 100 íL of phage suspension (amplified phages
before or after each selection round or suspensions from
single phage clones) preincubated with 100 íL of blocking
buffer for 20 min was added and the mixture incubated for
1 h. After the mixture had been washed with Tris-Bis, HRP-
conjugated anti-M13 antibody (Amersham Biosciences,
Uppsala, Sweden) diluted 1:5000 was added and incubated
for 1 h. Plates were washed with Tris-Bis, and bound phages
were detected via the HRP-conjugated antibody using TMB
and H2O2 (46). After 10-30 min, the colorimetric reaction
was stopped by addition of 100 íL of concentrated H2SO4.
Absorption at 450 nm was recorded with a Fluostar optima
microplate reader (BMG Labtechnologies, Offenburg, Ger-
many) at 450 nm.
DNA Sequence Determination. Single-stranded DNA was
prepared using a QIAprep 96 M13 kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
Sequencing was conducted using the Dye Terminator Cycle
Sequencing kit (PE Applied Biosystems, Warrington, U.K.),
and reaction products were separated by a 4% denaturating
urea PAGE and analyzed with an ABI Prism 377 DNA
sequencer equipped with the API Prism sequencing analysis
3.4.1 tool (Applied Biosystems, Langen, Germany). Sequence
analyses were performed with the “GCG” Wisconsin Pack-
age, version 10.3 (Genetic Computer Group Inv., Madison,
WI).
Spot Assay. Peptides bound to continuous cellulose
membrane supports were purchased from JPT Peptide
Technologies GmbH (Berlin, Germany). All peptides were
amino-terminally acetylated. Each spot carried 5 nmol of
peptide covalently bound to the cellulose membrane. For the
immunoassay, the membrane was blocked overnight with
T-TBS (TBS with 0.05% Tween 20) complemented with
10% FCS. After the membrane had been washed with
T-TBS, the membrane was incubated with 10 mL of T-TBS,
10% FCS, and the appropriate GST-SH3 fusion protein (1
íg/mL) for 4 h, followed by an additional washing step with
T-TBS. The membrane was incubated with a 1:2000 dilution
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of a HRP-conjugated anti-GST antibody (Novus Biologicals,
Inc., Littleton, CO) for 2 h and then washed three times with
T-TBS for 30 min. Bound antibody was quantified using
chemiluminescence detection (ChemiDoc, Bio-Rad, Mu¨nchen,
Germany) 1 min after addition of the substrate (Pierce
Biotechnology, Inc., Rockford, IL). Spot intensity values
were calculated with the Quantity One software tool from
Bio-Rad using background subtraction. The membrane was
regenerated by washing with H2O and sequential treatment
with 8 M urea supplemented with 10% SDS and 100 mM
2-mercaptoethanol overnight and then twice for 1 h, three
times for 1 h with 10% acetic acid in 50% ethanol, twice
for 30 min with T-TBS, three times for 1 h at 50 °C with
62.5 mM Tris-HCl (pH 6.7) and 100 mM 2-mercaptoethanol,
three times for 30 min with 10 PBS, and three times for
30 min with T-TBS.
Fluorescence Spectroscopy and Calculation of the Binding
Constants. Measurements of binding affinities based on the
interaction of the peptides with aromatic residues (predomi-
nantly tryptophan) in the SH3 domains were performed
essentially as previously described (43) using a Perkin-Elmer
LS 55 fluorescence spectrometer at excitation and emission
wavelengths of 290 and 345 nm (slit width, 3.4 nm),
respectively. A mini magnetic stirrer was used to mix the
solution in a 3 mL quartz fluorescence cell. The sample
temperature was held constant at 21.5 °C using a circulating
water bath. Peptides were purchased as reversed phase high-
performance liquid chromatography-purified products (JPT
Peptide Technolgies GmbH, Berlin, Germany) and were N-
and C-terminally acetylated and amidated, respectively.
Identities were confirmed by matrix-assisted laser desorption
ionization time-of-flight mass spectrometry (MALDI-TOF-
MS). To obtain the titration curves for calculating the binding
constants, peptides from stock solutions in H2O were added
in small increments to 1.6 mL of PBS and 1 mM DTT
containing the free SH3 domain at 0.5 íM. Upon addition
of the peptide solution, changes in fluorescence were
measured. The change of the protein concentration that
occurred as a result of peptide addition was properly
corrected with fluorescence values from a control titration
with the peptide being replaced with buffer. Because the PD1
peptide contains a tyrosine residue, the control titrations
contained buffer with tyrosine amide equal to the PD1
peptide concentration of the respective titration step.
The experimental data were fitted according to eq 1
where [Ltot] is the total peptide (ligand) and [Ptot] is the total
SH3 (protein) concentration at each measurement point, F
is the measured fluorescence intensity at the particular
peptide concentration, Fmax is the observed maximal fluo-
rescence intensity of the protein when saturated with the
peptide, and Fmin is the fluorescence intensity of the protein
at the titration start. We obtained eq 1 by solving the standard
1:1 stoichiometric binding equation KD ) [Pfree][Lfree]/
[complex], where [Pfree] ) [Ptot] - [complex] and [Lfree] )
[Ltot] - [complex] and subsequent replacement of [complex]
) [Ptot](F - Fmin)/(Fmax - Fmin) without applying simplifica-
tions. Nonlinear regression curve fitting was carried out to
fit the experimental data to the equation, with Fmax and KD
as fitted parameters.
RESULTS
In Vitro-Selected Lck SH3 Ligands Follow a Class I
Consensus Hxw(y/h)PLPplP. To determine the binding
specificity of the human Lck SH3 domain, we used recom-
binant GST-Lck SH3 fusion protein to screen a phage-
displayed random dodecapeptide library. After three selection
cycles, 20 single clones were randomly chosen for further
analysis. All of them were assayed for Lck SH3 binding
activity employing anti-phage ELISAs to eliminate false
positive clones. Altogether, 18 of the originally chosen
phages exhibited positive results. The amino acid sequences
of the peptides presented on these phages, as deduced from
DNA sequence analysis, are shown in Figure 1A. More than
60% of the obtained phages carried the same dominating
FIGURE 1: Phage display-selected peptides and their relative binding
affinities for Lck SH3. (A) Lck SH3 binding peptides selected by
phage display. Recombinant GST-Lck SH3 fusion protein was
used for biopanning of the phage display peptide library. The amino
acid sequences of peptides displayed by positive phage clones were
deduced from the DNA sequences of the corresponding gene III
fusions. Peptide sequences are given in the one-letter amino acid
code. Dark gray and gray bars indicate highly and moderately
conserved amino acids, respectively. To the right of the peptide
name, a number denotes how often the respective sequence was
found among the independent isolates. Below the class I sequence
list, the resulting consensus sequence is indicated. Uppercase letters
represent residues conserved in all sequences, and lowercase letters
represent residues that are found in at least 50% of the peptide
sequences. The proline residues belonging to the strictly conserved
PxxP motif of SH3 ligands and the amino acid which covers the
“compass position” P-3 are boxed. The designations of the positions
in the peptides sequences are according to ref 72. Sequence PD4
is additionally shown as class II ligand in the C- to N-terminal
direction from left to right, because binding of this peptide is
theoretically possible in both orientations. (B) Relative binding
affinities of the selected peptide sequences were estimated by an
anti-phage ELISA. Approximately 109 phage particles, displaying
the peptide indicated below each bar, were adsorbed to GST-Lck
SH3 protein-coated vials of a microtiter plate. Retained phages were
revealed by a HRP-conjugated anti-M13 antibody and TMB and
H2O2 as the substrate. For each phage clone, the mean value and
the standard deviation of 10 colorimetric reactions are shown.
F ) Fmin + [[Ptot] + [Ltot] + KD2 -
x([Ptot] + [Ltot] + KD)24 - [Ptot][Ltot]](Fmax - Fmin)[Ptot] (1)
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peptide, named “PD1”. All sequences obtained from the
screening procedure can be represented by the consensus
sequence N-Hxw(y/h)PLPplP (Figure 1A), where uppercase
letters represent residues conserved in all sequences and
lowercase letters show residues that are found in at least 50%
of the peptide sequences.
The core of the consensus sequence (LPplP) obtained from
the phage display screening (Figure 1A) nicely fits to the
common features of SH3 binding peptides. In detail, two
“LP” dipeptides were conserved in three of the four selected
peptides (PD1, PD2, and PD4) representing 17 of 18
sequences in total. The “bridging” proline residue, frequently
called a “scaffolding” residue (23), is present in PD1 and
PD3 peptides (Figure 1A). Additional residues of the ligand
that are N-terminal (class I) or C-terminal (class II) relative
to the proline-rich motif are able to form additional contacts
to the SH3 surface (23). Such “extra binding regions” were
reported and play a role in the affinity and specificity of
SH3-ligand complexes (47). On the basis of the positioning
of their “aliphatic-proline” dipeptides within the 12-mer
peptides, we assume a type I orientation for PD1-PD3,
although surprisingly none of them reveals the very common
positively charged amino acid at position P-3 (24, 39), which
usually contacts a conserved aspartate residue located at the
end of the RT loop via a salt bridge. In a control screen,
which was conducted under the same conditions as the
experiment described here, but using a different library lot,
again no arginine was selected at position P-3 (data not
shown). Likewise for PD4, the positioning of the aliphatic-
proline dipeptides argues for a type I orientation, but here a
lysine residue at the anchor position typically for a class II
ligand would also be consistent with binding in a type II
orientation. Thus, PD4 theoretically seems to be able to bind
SH3 domains in either one orientation or in both (Figure
1A).
To semiquantitatively determine the relative binding
affinities of the selected peptides for the Lck SH3 domain,
an anti-phage ELISA was carried out (Figure 1B). Peptide
PD1 exhibited the highest affinity for Lck SH3, followed
by peptide PD2 and peptides PD3 and PD4. This is in
accordance with the observed predominant occurrence of
PD1 (11 of 18 sequences) and PD2 (5 of 18 sequences) after
three selection rounds.
Potential Key Residues of the Selected Peptides for Lck
SH3 Binding outside the Proline-Rich Core. Two peptide
positions outside the proline-rich core motif that are com-
pletely (P-6) or moderately conserved (P-4) among the
selected sequences (Figure 1A) were further assayed for their
role in Lck SH3 binding. The invariant His residue at P-6
and the Trp residues in PD2 and PD4 at P-4 were exchanged
with alanine residues at the respective peptide positions and
probed for binding to Lck and other SH3 domains in the
spot assay (Figure 2A). Additional peptides were used to
check for unspecific binding to either acidic, basic, aromatic,
or polyalanine peptides. Only Fyn SH3 exhibited weak but
significant binding to the basic peptide. Spot intensities of
the Lck SH3 binding assay are more quantitatively sum-
marized in Figure 2B.
As expected, the replacement of the invariable prolines
(P0 and P3) within the proline-rich core motifs and residue
P-3 with alanines abolished interaction of these control
peptides with Lck and any other SH3 domain. The only
exception is binding of Fyn SH3 to the PD4 control peptide,
possibly due to its unspecific binding to basic peptides. PD3
did not exhibit binding to Lck SH3. This might indicate a
somewhat high threshold value for a positive binding signal
in the spot assay. Substitutions of the selected His residue
at P-6 with alanine [H(-6)A variants] completely weakened
PD1 and PD2 binding and significantly reduced the level of
binding of PD4 to Lck SH3. This is very surprising,
especially because binding of Hck, Src, and Fyn to PD1 H(-
6)A was not abolished (Figure 2A). PD2 and PD4 peptide
variants with tryptophan to alanine substitutions at position
P-4 [W(-4)A variants] also lost binding to Lck SH3 (Figure
2B).
ComparatiVe Binding Studies of the PD Peptides with
Different SH3 Domains. SH3 domain specificities of the Src-
type kinases Src, Hck, and Fyn are known to be very similar.
Therefore, we investigated the binding properties of the
phage display screening-obtained PD peptides and their
variants additionally with Src, Hck, and Fyn, but also with
Abl and PI3K SH3 domains (Figure 2A). Not surprisingly,
the spot patterns after binding to Lck and Src, and to a
somewhat lesser extent, Hck and Fyn SH3 domains, were
very similar to each other. The non Src-type Abl and PI3K
SH3 domains, in general, bound the PD peptides and their
variants with drastically reduced affinity, reflecting their
distinct ligand preference.
The most obvious difference among Lck, Src, Hck, and
Fyn SH3 domains is the role of histidine at position P-6. In
general, histidine at this position seems to be more important
for Lck than for Hck, Src, and Fyn SH3 binding. The
differences are small but significant. This will be shown in
more detail using a substitution analyses for Lck and Src
SH3 domains, as will be described later in the text. Another
interesting difference among Lck, Src, Hck, and Fyn SH3
domain binding is recognition of the PD2 peptide. Only Lck
and Src SH3 show a detectable interaction with the PD2
peptide, whereas the Hck and Fyn SH3s seem to bind only
its H(-3)R variant. Further, on the basis of its amino acid
sequence, peptide PD4 is principally able to bind in both,
type I and type II, orientations. It contains a histidine at the
anchor position (P-3) if binding is in the type I orientation.
Lysine occupies the anchor position if binding is anticipated
in the type II orientation. To elucidate the orientation of
binding of PD4 to the SH3 domains under investigation,
peptide variants PD4 H(-3)A and PD4 K(+5)A were used
for spot binding assays. Interaction with the PD4 H(-3)A
peptide would suggest PD4 to be bound by the respective
SH3 domain in the type II orientation. On the other hand,
interaction with the PD4 K(+5)A peptide argues for the type
I orientation of the bound peptide. Our results clearly indicate
a type I orientation of PD4 when interacting with Lck and
Src SH3s, and a type II orientation when interacting with
the SH3 domains of Hck or Fyn. It is notable that the reported
PD4 orientation difference is not detected with variant PD4
H(-3)R having the strong arginine anchor at position P-3.
This peptide variant yielded very strong signals for all four
Src-type PTK SH3 domains, which would argue for a type
I orientation of PD4 H(-3)R in each case.
As already mentioned for Lck SH3 (Figure 2B), substitu-
tion of tryptophan at position P-4 with alanine abolished
binding of PD2 to Src SH3, and of PD4 to Src and Hck
SH3, too. Thus, in the originally selected peptides, the
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presence of an aromatic amino acid at this position is required
for binding. The situation is not clear for Fyn SH3 and PD4
W(-4)A. Unspecific binding seems to make a substantial
contribution to the binding of Fyn SH3 to PD4 and its
variants.
The Selected Histidine and Tyrosine Residues at Ligand
Position P-3 Are Suboptimal for Lck SH3 Binding Affinity.
With the exception of Abl, the “compass” pockets of most
SH3 domains contain a common acidic residue at the end
of the RT loop, which is responsible for the preference of
arginine (or sometimes lysine) at ligand position P-3 im-
mediately preceding (binding in the type I orientation) or
following (binding in the type II orientation) the core proline-
rich sequence of the peptide ligand (24). The presence of a
neutral residue at the respective position in the Abl SH3 RT
loop is in accordance with its preference for aromatic residues
at position P-3 (31, 48). The SH3 domain of Lck, like those
of most other Src-type tyrosine kinases, contains an aspartic
acid residue at the relevant RT loop position (D79). Thus, it
is unexpected that none of the peptides identified in the
screening procedure contains an arginine at position P-3. At
least one peptide without a basic residue, actually with a
tyrosine, at position P-3 was described that binds to the SH3
domain of Fyn. The 3BP2-derived peptide PPAYPPPPVP,
which is a physiological Abl ligand, is able to bind Fyn SH3
(49), although this may not be physiologically relevant (50).
To investigate the role of the histidine or tyrosine residues
in PD1-PD4 at position P-3 for Lck SH3 binding, variants
thereof carrying arginine instead of tyrosine or histidine at
position P-3 were investigated for binding to GST-tagged
Lck SH3 in the spot assay. Indeed, affinity for Lck SH3 was
increased for all four peptide variants (Figure 2A). Obviously,
the presence of an arginine residue at position P-3 enhances
ligand affinities of the peptides for Lck SH3 (Figure 2B). In
the case of PD3, binding affinity was detectable only for
the arginine variant. The arginine variant of PD1 [PD1-Y(-
3)R] showed a 2-fold increase in affinity compared to that
of PD1 as measured by the changes in the intrinsic Lck SH3
tryptophan fluorescence upon binding of the corresponding
synthetic peptides PD1 and PD1-Y(-3)R (Table 1). Thus,
the selection procedure yielded peptide sequences which were
at least in the case of ligand position P-3 not affinity
optimized. This might be explained by the great but limited
diversity of the phage-displayed peptide library used for the
screening. Additionally, it is known that arginines in the
random peptide sequences of phage display libraries interfere
with the secretion of the minor coat protein to which they
are fused as well as with phage infectivity. Therefore, peptide
variants with basic residues are slightly underrepresented in
the starting library (51). Also, we cannot exclude the
possibility that, under the screening conditions that were
used, phage-fused peptides with His or Tyr at position P-3
FIGURE 2: Affinities of the phage-selected peptides and variants thereof for Lck and other SH3 domains. (A) Analyses of the binding
affinities of the phage-selected peptides and variants for different SH3 domains using the spot membrane technology. After incubation with
one of the different GST-SH3 domains, the peptide-bound SH3 fusion proteins were detected by a HRP-conjugated anti-GST antibody
and visualized by chemiluminescence. Names and sequences of the immobilized peptides as well as the used GST-SH3 domains are
given. Variations of the originally selected peptides are shown in italics and are part of the peptide names with the affected peptide position
given in parentheses. The proline residues belonging to the strictly conserved PxxP motif of SH3 ligands and the amino acid which covers
P-3 are in bold. To ensure proper spacing of the PxxP motifs from the membrane support, all PD2 and PD4 peptides have been C-terminally
elongated by two glycine residues. (B) Quantitative representation of the spot intensities obtained after incubation of the membrane with
the GST-Lck SH3 fusion protein. Intensities for each peptide position were determined after background subtraction. The arrangement of
the peptides is in the same order as in panel A.
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are in the case of Lck SH3 binding in fact more positively
selected than peptides with Arg at the corresponding position,
e.g., because of a more favorable ratio of association and
dissociation rates of such phages.
Position P-6 of PD1-Y(-3)R Is Preferably Occupied by
Histidine and May Be a Specificity Determinant for Lck SH3
Binding. Phage-fused PD1 exhibited the highest relative
affinity for Lck SH3 of the phage-selected peptides (Figure
1B), and its engineered variant PD1-Y(-3)R exhibited a KD
of 25 íM, a 2-fold enhanced affinity for Lck SH3 (Table
1). Therefore, PD1-Y(-3)R seems to be a promising
candidate for designing a high-affinity Lck SH3 ligand. We
performed a substitution analysis on the basis of PD1-Y(-
3)R. Four of the five sequence positions (P-2, P-1, P0, and
P3) that were invariant among the PD peptides and the
arginine at position P-3 were kept constant. All seven other
positions were substituted with all 19 other amino acids
(Figure 3A). Whenever histidine at P-6 is exchanged with
another amino acid, binding to Lck SH3 is almost completely
abolished. Only if the histidine is exchanged with arginine
approximately one-third of the binding affinity is retained.
This is in perfect agreement with the phage display screening
result.
Figure 3B summarizes the spot intensities of the P-6
substitution peptides incubated with Lck and Src SH3
domains. Src SH3 also favors histidine at position P-6.
However, a variety of substitutions (Arg, Lys, Ile, Leu, Pro,
and Phe) are well tolerated. Thus, histidine at position P-6
seems to be a strong specificity determinant for Lck SH3
peptides that bind in the type I orientation.
Substitution Analysis ReVeals Variants with Increased Lck
SH3 Binding Affinity Compared to That of PD1-Y(-3)R.
Obviously, ligand positions P-5, P-4, P1, P2, P4, and P5
tolerate a variety of different substitutions (Figure 3). This
is in accordance with the observed sequence variation among
the PD peptides at these positions. Most of the single-amino-
acid-substituted peptide derivatives of PD1-Y(-3)R bind to
Lck SH3 with affinities similar to that of PD1-Y(-3)R.
Binding affinity seems to be dramatically increased when
positions P-5 and P-4 are replaced with Phe and Arg,
respectively. Other substitutions do not seem to contribute
that much. In general, the level of binding is reduced
drastically when any position tested is replaced with Trp,
Tyr, Cys, Asp, or Glu. Peptide HFKRPLPPLPS with a S(-
5)F substitution shows the strongest signal of all tested
variants and documents that even the engineered PD1-Y(-
3)R peptide constitutes a suboptimal Lck SH3 ligand.
The Engineered PD1-Y(-3)R Ligand Belongs to a Group
of Special Class I Ligands. With PD1, PD2, and PD4, three
of our four phage-selected sequences have leucines at
positions P-1 and P2 (Figure 1A), and therefore fulfill the
requirements for a special type of class I ligand (Lig-I′),
recently introduced by Serrano and co-workers (52). Briefly,
Lig-I′ ligands are characterized by their ability to bind to
SH3 domains with a conserved Trp conformation normally
supporting binding of class II ligands (SH3-II domains). The
engineered high-affinity PD1-Y(-3)R peptide belongs to this
special type of class I ligands, too. Only PD3 does not match
exactly, as ligand position P2 is occupied by Phe instead of
Leu. It is notable that the PD3 peptide did not bind to any
of the assayed SH3 domains in the spot membrane assay
(Figure 2A). From these results, we conclude that the
conserved Trp in Lck SH3 might possibly prefer the SH3-II
conformation. Supportively, Figure 4 summarizes the binding
of Lck SH3 to a set of partially very similar ligand peptides,
which were described as preferred ligands for the SH3
domains of Src, Fyn, PI3K, Abl, and Hck (42). In accordance
with a probable preference for SH3-II conformation, Lck
SH3 shows the tightest binding to three slightly different
class II ligands. Binding of Lck to a class I′ ligand was
Table 1: Affinity Measurements of Artificial Peptides PD1 and
PD1-Y(-3)R and Peptides Derived from Native Lck SH3 Binding
Proteins with the Lck SH3 Domaina
peptide KD (íM) peptide KD (íM)
PD1 46.2 ( 0.4 Sos-2 34.6 ( 1.8
47.3 ( 2.5 42.1 ( 2.3
PD1-Y(-3)R 24.8 ( 1.4 NS5A-6 20.5 ( 0.7
21.8 ( 0.9 22.2 ( 0.6
Sam68-1 115.9 ( 11.4
168.0 ( 13.4
a The values were determined from fluorescence titration experi-
ments. Each measurement was carried out in duplicate, and the standard
deviation of each experiment is given. The amino acid sequences of
the peptides are HSKYPLPPLPSL (PD1), HSKRPLPPLPSL [PD1-Y(-
3)R], PSRQPPLPHRSRGG (Sam68-1), VPVPPPVPPRRRPES (Sos-
2), and TKAPPIPPPRRKRTV (NS5A-6).
FIGURE 3: Amino acid substitution analysis of PD1-Y(-3)R. (A)
Substitution analyses of the engineered phage-selected peptide PD1-
Y(-3)R. Positions P-6, P-5, P-4, P1, P2, P4, and P5 of the PD1-
Y(-3)R sequence were substituted with all other proteinogenous
amino acids (given in one-letter code) and tested for binding to
Lck SH3 (the manual assembly of spots in columns A and C was
necessary due to an assignment aberration during membrane
synthesis). For Lck SH3, every substituted position is shown, and
for Src SH3, only position P-6 is shown. As a control, a column
with PD1-Y(-3)R peptide spots is indicated at the right. PD1-Y(-
3)R peptides within the substitution membrane are encircled. (B)
Plot of the spot intensities of position P-6 obtained after incubation
of the membrane with GST-Lck SH3 (black bars) or GST-Src
SH3 (gray bars) protein; the intensities for each peptide position
was estimated as described in Materials and Methods. The
arrangement of the peptides is in the same order as in panel A.
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significant, although to a lower extent. Two different class
I ligands yielded no or very weak binding to Lck SH3.
Interestingly, the weak binding class I ligand contains one
LP dipeptide required for class I′ binding. The other Src-
type PTK SH3 domains did not show such a clear preference
for the appointed class II ligands, possibly indicating a more
promiscuous orientation of their conserved Trp residues
compared to that of Lck SH3. As expected, beside Abl SH3
itself, none of the other SH3 domains bound to the preferred
Abl SH3 ligand.
Exploring the Lck SH3 Binding Regions of NatiVe Lck SH3
Ligands. Only a small number of exact Lck SH3 binding
sites within its native ligands are known. Therefore, we
intended to identify as many of them as possible. Nearly all
described Lck SH3 binding proteins play, often beside other
functions, a role in the activation process of T-cells or are
from viral sources interfering with T-cell activation, con-
sistent with the cell-type specific distribution of Lck. All
known Lck SH3 ligands were searched for regions that match
simplified criteria for classical SH3 binding: “+xPxxP” for
type I and “PxxPx+” for type II orientation. In cases where
the original Lck SH3 binding experiments were carried out
with peptides, which did not originate from human sources
(e.g., mouse in the case of LckBP1 and FasL), we used the
human counterparts in our study to refer to the physiological
situation as close as possible. From each region that contains
a potential SH3 binding motif, peptides comprising 15 amino
acids were deduced. As in case of NS5A, more than one
SH3-binding motif was found within a 15-mer peptide. Thus,
peptide variants with an alanine substitution of the respective
anchor residues were analyzed, too. The respective synthetic
peptides were immobilized on a cellulose membrane, and
binding to the GST-Lck SH3 protein was assayed by an
anti-GST ELISA (Figure 5).
In the case of ADAM15, CD2, CD28, HS1 (the human
homologue of LckBP1), Nef, NS5A, SLP76, Sos, Tio, and
TIP data are available regarding the position of the SH3
binding motif within the different proteins (10, 12, 13, 15-
17, 43, 53-55). These proteins act as internal controls with
which the degree of reliance of our experiment could be
measured. The results of the spot assay agreed very well
with the previously published data for ADAM15, CD2, HS1,
SLP76, Nef, NS5A, Tio, and TIP, even though completely
different methods had been used there to determine the
regions relevant for Lck SH3 binding (e.g., peptide competi-
tion, immunoprecipitation, or deletion mutant analysis). For
Sos, strong interaction with peptide 2 and a weaker one for
FIGURE 4: Binding of Lck and other SH3 domains to ligands of
different classes. The experimental setup is as in Figure 2. The
membrane was incubated with GST-SH3 fusion proteins as
indicated at the left. Immobilized peptide sequences have been taken
from previously reported studies from others, in which a preferred
ligand for a certain SH3 domains had been selected (summarized
in ref 42). Ligands a (RPPVPPRPGT), b (RPPVPPRPMT), c
(RAARPLPPLPP), and d (PPPYPPPPP) are preferred ligands for
Src, Fyn, PI3K, and Abl SH3 domains; ligands e (RRFRPLPPPP)
and f (RPPVPPRPST) have been identified as preferred Hck SH3
ligands. The corresponding ligand class is indicated: I, Lig-I; I′,
Lig-I′; and II, Lig-II.
FIGURE 5: Analysis of binding of Lck SH3 to peptides from
physiological ligands. Spot analyses of the binding affinities of
peptides derived from known physiological Lck SH3 binding
partners to Lck SH3. After incubation with GST-Lck SH3 protein,
peptide-bound SH3 fusion protein was detected by a HRP-
conjugated anti-GST antibody and visualized by chemilumines-
cence. Peptides for immobilization were chosen as described in
the text. Peptide names are given at the left. The respective peptide
number is given at the top. All peptides are numbered according
to their occurrence in the protein sequence and may therefore have
a different numbering scheme as in the cited literature. Accession
numbers of the used proteins as well as the position of the first
amino acid of the deduced 15-mer peptides are given in parentheses.
c-Cbl (P22681): c-Cbl-1 (490), c-Cbl-2 (527), c-Cbl-3 (536),
c-Cbl-4 (541), c-Cbl-5 (816). ADAM15 (AAH14566): ADAM15-1
(742), ADAM15-2 (762), ADAM15-3 (797). Cbl-b (Q13191): Cbl-
b-1 (420), Cbl-b-2 (500), Cbl-b-3 (543), Cbl-b-4 (557), Cbl-b-5
(581), Cbl-b-6 (668), Cbl-b-7 (773), Cbl-b-8 (818), Cbl-b-9 (863),
Cbl-b-10 (898), Cbl-b-11 (970), CD2 (NP_001758, 297), CD28
(NP_031668, 201). FasL (AAO43991): FasL-1 (17), FasL-2 (39),
FasL-3 (51), FasL-4 (62), FasL-5 (127). HS1 (P14317): HS1-1
(269), HS1-2 (319), HS1-3 (338). MAPK3 (P46734): MAPK3-1
(30), MAPK3-2 (281). MAPK4 (P45985): MAPK4-3 (23),
MAPK4-4 (385). Nef: HIV-1NL4-3 Nef (AAB60579, 68), HIV-
1SF3 Nef (AAC68849, 68), SIVmac239 Nef (AAL78997, 100). NS5A
(AAC15732, strain HC-J4): NS5A-1 (22), NS5A-2 (339), NS5A-3
(344), NS5A-4 (344, R356A substitution), NS5A-5 (344, K348A
substitution), NS5A-6 (347), NS5A-7 (347, R356A substitution),
NS5A-8 (347, K348A substitution). Sam68 (NP_006550): Sam68-1
(34), Sam68-2 (59), Sam68-3 (81), Sam68-4 (295), Sam68-5 (327),
Sam68-6 (352), Sam68-7 (420). SLP76 (Q13094): SLP76-1 (182),
SLP76-2 (400). Sos (NP_005624): Sos-1 (1020), Sos-2 (1147),
Sos-3 (1173), Sos-4 (1207), Sos-5 (1284). TIO (NP_047977,
184): TIP (P22575, 171). Inset: m (mouse), h (human), FasL-4
(mouse) (A53062, 62), FasL-4 (human) (AAO43991, 63). No
binding of Lck SH3 to any peptide of the following proteins was
detected in our study. hDlg (NP_004078): hDlg-1 (64), hDlg-2
(152), hDlg-3 (165), hDlg-4 (170). SH2-kinase linker Lck (P06239,
223). PI3K (NP_002640): PI3K-1 (303), PI3K-2 (365), PI3K-3
(555), PI3K-4 (779). PI4K (P42356): PI4K-1 (136), PI4K-2 (360),
PI4K-3 (375), PI4K-4 (522). WASP (Q92558): WASP-1 (184),
WASP-2 (270), WASP-3 (318), WASP-4 (347), WASP-5 (363),
WASP-6 (380), WASP-7 (423), WASP-8 (461).
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peptides 3 and 5 are described (15). The study presented
here yielded strong binding of Lck SH3 to Sos peptide 2
and, to some lesser extent, to Sos peptides 4 and 5. Whether
this minor discrepancy is due to the fact that the peptides
used in this study carried two additional residues is not clear.
Interaction of Lck SH3 with the CD28-derived peptide was
somehow weak, but detectable.
In contrast to the above-mentioned proteins, the positions
of the relevant Lck SH3 binding regions within c-Cbl, Cbl-
b, hDgl, FasL, MAPK3, MAPK4, PI3K, PI4K, Sam68, and
WASP have not been identified so far (9, 11, 18-20, 56-
58). Because the assayed phosphatidylinositol kinase se-
quences (PI3K and PI4K) do not include regions matching
any criteria for classical SH3 binding motifs (+xxPxxP for
type I and PxxPx+ for type II), we probed all PI3K/PI4K
regions containing a rudimentary “PxxP” motif. None of the
respective PxxP-containing peptides resulted in a detectable
interaction with the GST-Lck SH3 protein (data not shown).
Also, no binding was found for all probed regions of hDgl,
the SH2 kinase linker region of Lck, and WASP (data not
shown). Since short peptides are immobilized on the spot
membrane, our experimental approach is restricted to Lck
SH3 interaction partners comprising continuous, independent
SH3 binding epitopes. Thus, one possible explanation for
the negative results of PI3K/PI4K, hDlg, WASP, and the
SH2 kinase linker region of Lck might be that in some cases
isolated peptides might not reflect necessarily the situation
of the whole protein context. The SH2-CD linker region of
Src and Abl show, for example, a context-driven PPII
conformation, which means that SH3 binding of these regions
can only be observed in the presence of the scaffolding kinase
domains (59, 60). In the case of MAPK, we could find a
weak interaction of Lck SH3 with peptide MAPK3-1 (Figure
5), whose sequence (mskppapnptpprln) deviates from the
classical SH3 binding motif. For the proteins c-Cbl, Cbl-b,
Sam68, and human FasL, however, we were able to locate
the putative Lck SH3 binding sites within these proteins
(Figure 5).
PutatiVe Lck SH3 Interaction Sites in c-Cbl and Cbl-b,
Sam68, and FasL. The multifunctional proteins c-Cbl and
Cbl-b are members of a family of proto-oncogenes involved
in signal transduction. Both proteins are expressed in
haematopoietic cells and share structural similarities char-
acterized by an N-terminal SH2 domain, a RING-type zinc
finger domain that interacts with E2 ubiquitin conjugating
enzyme, and a C-terminal proline-rich domain. Cbl family
proteins negatively regulate T-cell activation by promoting
ligand-induced TCR down-modulation (61). A direct interac-
tion of Lck SH3 was demonstrated with c-Cbl (9), which is
a lipid raft-excluded protein and negatively regulates Lck
localization in lipid rafts upon binding to it. Only peptide
c-Cbl-5 (aa 816-830, gsqvperppkpfprr) within in the proline-
rich region yielded a detectable interaction signal with Lck
SH3 (Figure 5). Within Cbl-b, we identified three peptide
sequences as putative binding sites for Lck SH3. Peptide
Cbl-b-9 (aa 863-877, asgqvplpparrlpg) is the strongest
putative Lck SH3 binding site in Cbl-b. Peptides Cbl-b-7
(aa 773-786, sdpvplpparppt) and Cbl-b-10 (aa 898-911,
gsqaparppkprpr) yielded slightly weaker binding signals
(Figure 5). We therefore suggest regions of residues 863-
877, 773-786, and 898-911 to be the putative Lck SH3
binding sites in Cbl-b.
Sam68 is a RNA-binding protein that has been found to
be associated with c-Src and to be phosphorylated during
mitosis (62, 63). Sam68 is composed of five proline-rich
domains, a C-terminal tyrosine-rich region, and a KH
domain. Therefore, Sam68 is able to recruit various polypro-
line-binding proteins. Sam68 seems to act as an adapter
molecule participating in various signaling pathways, thereby
forming interactions with different PTKs via their SH3 and
SH2 domains dependent on cell type and activation state. In
fibroblasts, Sam68 mainly interacts with c-Src (64); in the
HTLV-1-infected Hayai cell line, Sam68 exhibits preferred
binding to Fyn, and in uninfected Jurkat T-cells, binding of
Sam68 to Fyn and Lck has been reported (20). In addition,
interaction of Sam68 with the p86 subunit of PI3K was
described previously (64). Spot analysis revealed a clearly
preferred Lck SH3 binding site in Sam68-1 (aa 34-48,
psrqpplphrsrgg). Peptides Sam68-4, -5, and -7 (aa 295-309,
pppppvprgrgvgpp; aa 327-341, atvtrgvpppptvrg; aa 420-
434, rpslkapparpvkga) bound to Lck SH3 with significantly
reduced affinity. This suggests residues 34-48 of Sam68 to
be the dominating Lck SH3 binding site in Sam68.
A couple of reports show a cooperation of Lck and human
FasL activity (65-68). The Fas/FasL (Apo-1) system plays
an important role in T-cell homeostasis (69). We checked
possible binding of Lck SH3 to peptides comprising several
regions within human FasL. A positive result was obtained
for peptide FasL-4 comprising residues 62-76 (plpplplp-
plkkrgn) (Figure 5). Previously, it was shown that human
Fyn, but not the Lck SH3 domain, directly binds to a
synthetic peptide comprising residues 60-71 (qplplppltplk)
of the mouse FasL protein (57). There are several differences
in the amino acid sequences of mouse FasL and human FasL
in the relevant region (Figure 5, inset). To control whether
the assay used in our study is responsible for the somehow
different result in binding of Lck SH3 to FasL, we decided
to carry out an additional assay with peptides derived from
mouse and human FasL in parallel (Figure 5, inlet). In
agreement with the results of Hane and co-workers, Lck SH3
did not bind to the mouse FasL peptide in our study, either.
But Lck SH3 reproducibly did bind to the human FasL
peptide. Thus, according to our results, sorting and localiza-
tion of human FasL could in principle be affected by SH3
domains other than Fyn SH3. More comprehensive experi-
ments are necessary to confirm the interaction of FasL with
Lck SH3 in living human cells. Confirmed binding between
FasL and Lck in human but not in mouse would be a very
interesting example of a species specific difference.
Natural Lck SH3 Ligands Bind Very Likely in the Type II
Orientation. To identify common schemes among the Lck
SH3 binding sites within its native ligands, all peptide
sequences with binding spot intensities higher than 1000
arbitrary units, as estimated according to the approach
described in Materials and Methods, are summarized in
Figure 6. The peptide sequences agree to the consensus
N-gxp(v/p)Pl(l/p)PPRprpr, where the residues depicted with
bold uppercase letters are found in all peptides, residues
depicted with uppercase letters are found frequently, and
residues depicted with lowercase letters are moderately
conserved at the corresponding position in each peptide (x
designates a residue without obvious preference for a specific
amino acid). The core of the consensus is very similar to
the ¾Pp¾Pp+ pattern of typical class II ligands (24). Thus,
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very strikingly and without exception, all peptides from
natural Lck SH3 ligands exhibit features for binding in the
type II orientation.
Overall, positions P-6, P-4, P3, and P4 tend to be occupied
by prolines. It is notable that with only a few exceptions (P4
in Nef_SF2 and Sos-2, and P5 in Tio), no hydrophobic amino
acids occur at ligand positions P-4, P4, and P5. Aromatic
amino acids do hardly occur, and cysteines do not at all
appear at any position.
A positive net charge in the region comprising ligand
positions P-7-P-4 seems to be favorable, as deduced from
overall 16 positively and three negatively charged amino
acids in that region among all peptides shown in Figure 6.
Thus, peptide binding seems to be dependent on the presence
of one or more auxiliary arginine residues located in the
proximity of the P-3 “anchor residue”. Contrary to the phage
display-derived peptides, outside the core motif no dominant
amino acid could be found at any position.
DISCUSSION
From our results, it is obvious that all peptides derived
from native Lck SH3 binding proteins that were assayed for
Lck SH3 binding with positive results belong to class II
binders (Lig-II). The peptides obtained from the phage
display screening approach, however, are ligands of Lck SH3
following the type I orientation. As already mentioned, they
all belong to the special type of class I′ peptides (Lig-I′),
introduced and described in detail by Serrano and co-workers
(52). In summary, they found that the side chain of a
conserved Trp in the SH3 binding pocket can adopt two
different orientations, classifying the respective SH3 domain
structure, free or in complex, to be SH3-I and SH3-II. The
orientation of the conserved Trp depends on the nature of a
second residue located at a key position (residue 132 in Fyn,
homologue to residue 110 in Lck) near the binding pocket.
SH3 domains with â-branched or long aliphatic residues at
this key position force the conserved Trp to adopt the SH3-
II orientation, whereas SH3 domains with aromatic residues
in this key position are assumed to be promiscuous (52).
The general rule concluded from their study is that Lig-I
peptides bind to SH3-I domains and Lig-II peptides bind to
SH3-II. Exceptions are Lig-I′ peptides with Leu at position
P-1 and Leu or Ala at position P2. According to their
experiments, these two amino acids allow dihedral angle
combinations that are not allowed for Pro residues mostly
present in Lig-I ligands at the respective positions. Conse-
quently, Lig-I′ peptide backbones deviate from an ideal PPII
helix and follow the trajectory of a Lig-II peptide, instead
of Lig-I. Therefore, Lig-I′ peptides bind to SH3-II domains,
while maintaining the type I binding orientation.
Because a Phe is in the key position of Lck, a promiscuous
binding behavior of Lck SH3 has been predicted (52). Thus,
a mixture of Lig-I, Lig-I′, and Lig-II peptides was expected
to be the result of the phage display screening search for
artificial Lck SH3 ligands. The exclusive observation of Lig-
I′ peptides from the in vitro selection and the exclusive
identification of Lig-II peptide sequences in Lck SH3’s
physiological binding partners suggest that in addition to the
key residue other factors which govern the orientation of
the conserved Trp residue exist. This is consistent with the
three available structures of the ligand-free Lck SH3 domain
[PDB entries 1H92, 1KIK, and 1LCK (43, 44, 70)], which
all are SH3-II, although the key residue is a Phe.
One of the most striking questions arising from this study
is why the in vitro-selected peptides are Lig-I′ and the
peptides derived from the native ligands of Lck SH3 are Lig-
II. To elucidate whether both ligand types show differences
in their binding affinities, we determined the KD values for
the interactions of Lck SH3 with the artificial peptides PD1
and PD1-Y(-3)R and with peptides Sam68-1, Sos-2, and
NS5A-6. Dissociation constants between 20 and 170 íM
were obtained (Table 1), and the values of Lig-I′ and Lig-II
peptides are similar. Obviously, the KD value alone is not
the crucial parameter that can explain the observed class I
and class II restrictions for in vitro-selected peptides and
those obtained from physiological ligands, respectively. In
this context, it is very interesting that the vast majority of
SH3-Lig-I′ three-dimensional complex structures deter-
mined so far by nuclear magnetic resonance spectroscopy
and by X-ray crystallography contain Lig-I′ peptides that
originate from in vitro selection studies (PDB entries 1IO6,
1NLO, 1NLP, 1AWF, 1RLP, and 1RLQ). The only excep-
tions are two structures of Fyn SH3 with a peptide compris-
ing residues 91-104 of p85 PI3K (PDB entries 1AON and
1AZG) with an Ala residue instead of Leu at ligand position
P2. Also, high-affinity SH3 binding peptides obtained from
phage display studies against other Src-type SH3 domains
(30, 31), tend to be Lig-I′. The reason for this is not clear.
These findings, together with our study, strongly suggest that
in vitro-derived SH3 ligands be examined with caution when
they are being compared with native ligands. A thermody-
FIGURE 6: Multiple-sequence alignment of physiological Lck SH3
ligands. Alignment and ranking of the Lck SH3 binding peptides
from the analyzed physiological binding partners. The ranking of
the peptides is based on the spot intensity values from Figure 5,
which were obtained as described in Materials and Methods.
Binding strength was classified semiquantitatively according to the
gained intensity values (arbitrary units). Peptides with values above
2500, 1500, and 1000 can be found in the top, middle, and bottom
parts of the alignment, respectively. Please note that as in Figure
1, the designations of the peptide sequence positions are according
to Lim and co-workers (72), resulting in a C- to N-terminal direction
from left to right for all class II ligand peptides.
15050 Biochemistry, Vol. 44, No. 45, 2005 Tran et al.
namic dissection of the binding energetics of proline-rich
peptides with Abl SH3 showed striking and somewhat
unexpected effects of slight modifications in peptide se-
quence on the enthalpic and entropic contributions of the
respective binding interactions (71), confirming the complex-
ity of SH3-ligand interactions.
It is obvious that physicochemical parameters for a
complex formation under in vitro screening conditions with
maximum diffusion rates of all molecules involved and in
the absence of competing SH3 domains are completely
different from the situation in a living cell, with drastically
decreased diffusion rates of all molecules involved and in
the presence of proteins that compete for a given ligand. This
may explain the observed Lig-I′ preference of Lck SH3
during a phage display selection approach. Further investiga-
tions are required to obtain comprehensive insight into the
biophysical properties that biological complexes need to exert
to be functional in living cells.
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